FORTE: Induction With Carfilzomib, Dexamethasone, and Cyclophosphamide or Lenalidomide in Newly Diagnosed MM

Source: 2017 American Society of Clinical Oncology Annual Meeting*
Download Slideset
June 2-6, 2017; Chicago, Illinois
KCd use was associated with a lower rate of nonhematologic AEs and improved odds for PBSC mobilization vs KRd use.
Format: Microsoft PowerPoint (.ppt)
File Size: 599 KB
Released: June 7, 2017

Acknowledgements

Supported by educational grants by
AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings